leadf
logo-loader
viewCo-Diagnostics

Co-Diagnostics to expand coronavirus testing services by Arches Research using its Logix Smart test kit

Arches Research, a CLIA laboratory and subsidiary of Polarity TE Inc, began using Co-Diagnostics' tests for its customers earlier this year

covid
Arches received a CLIA certificate of registration at the end of April and began testing for COVID-19 shortly thereafter

Co-Diagnostics Inc (NASDAQ:CODX) (FRA:C97) announced Tuesday that it has entered into an agreement with Arches Research Inc to expand Arches' coronavirus (COVID-19) testing services using Co-Diagnostics' Logix Smart COVID-19 test kit.

Arches Research, a CLIA laboratory and subsidiary of Polarity TE Inc (NASDAQ:PTE), began using Co-Diagnostics' tests for its customers earlier this year, according to a statement. 

Co-Diagnostics said the announcement follows news last week of additional, independent third-party validation of its COVID test, supporting its performance characteristics and value in helping communities, schools, and workplaces to re-open safely.

READ: Co-Diagnostics is augmenting its Logix Smart COVID-19 test kit to prepare for the flu season

"We are pleased to have this opportunity to further expand our relationship with one of our valued CLIA lab clients to help meet demand for COVID-19 testing,” said Dwight Egan, CEO of Co-Diagnostics.

“Arches has been an important customer in the ongoing battle against the coronavirus, and we expect this agreement will also create opportunities for sales of additional molecular diagnostic products in our development pipeline, including our upcoming Logix Smart Flu A/Flu B/COVID-19 test kit."

Co-Diagnostics’ Logix Smart COVID-19 test is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes the COVID-19 disease, in the US and many other countries.

The Utah-based company noted that Arches received a CLIA certificate of registration at the end of April and began testing for COVID-19 shortly thereafter. CLIA is regulated by the Centers for Medicare & Medicaid Services, with a primary goal to ensure quality laboratory testing.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Co-Diagnostics

Price: 15.17 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $426.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

2 min read